InvestorsHub Logo
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: eb0783 post# 198146

Monday, 12/01/2014 5:09:40 AM

Monday, December 01, 2014 5:09:40 AM

Post# of 346262
ECYT had 260% higher PFS (statstically significant) than control arm in phase 2 (PRECEDENT trial).

But phase 3 (PROCEED trial) failed due to control arm performing at its best ever.

My point is, there are no guarantees that a 133% pfs/os improvement in p2 with bavi would result in successful p3.

Though improvement at both the doses looks more promising, nothing is a given.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News